DEF: IDEAYA Biosciences Schedules 2026 Annual Meeting

IDEAYA Biosciences, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026, to elect directors, ratify auditor selection, and vote on executive compensation.

Summary

• IDEAYA Biosciences, Inc. is holding its 2026 Annual Meeting of Stockholders on June 16, 2026, at 1:30 p.m. Pacific Time, conducted entirely online.
• The meeting's agenda includes the election of three Class I directors, ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and an advisory vote on executive compensation.
• Stockholders of record as of April 20, 2026, are eligible to vote.
• The company is utilizing a 'notice only' option for delivering proxy materials, with a Notice of Internet Availability mailed on or about April 29, 2026.
• The Board of Directors recommends voting 'FOR' all three proposals.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it pertains to routine corporate governance matters and does not contain new financial performance data or strategic announcements that would significantly alter the company's valuation.

Positives

• The company is holding its annual meeting to ensure continued corporate governance and stockholder engagement.
• The online format aims to provide expanded stockholder access and participation.
• The Board of Directors is seeking stockholder ratification for key decisions, demonstrating a commitment to good corporate practice.
• The company has a robust corporate governance framework, including a Code of Business Conduct and Ethics, Corporate Governance Guidelines, and independent board committees.

Risks

• The filing does not contain specific forward-looking financial guidance or performance metrics, making it difficult to assess future financial performance directly from this document.
• While not explicitly stated as a risk, the reliance on advisory votes for executive compensation means that significant stockholder dissatisfaction could lead to future compensation adjustments.

Future Outlook

The filing primarily concerns the upcoming annual meeting and does not contain specific forward-looking financial guidance. However, it outlines the process for future stockholder proposals and the timeline for the 2027 annual meeting.

Management Comments

• "I am pleased to invite you to attend the 2026 Annual Meeting of Stockholders (the Annual Meeting) of IDEAYA Biosciences, Inc. (IDEAYA), which will be held online at www.proxydocs.com/IDYA , on June 16, 2026 at 1:30 p.m. Pacific Time."
• "Whether or not you attend the Annual Meeting online, it is important that your shares be represented and voted at the meeting. Therefore, I urge you to promptly vote and submit your proxy via the Internet, by phone or by mail."
• "On behalf of the Board of Directors, I would like to express our appreciation for your interest in IDEAYA."

Industry Context

StockSavvy.ai notes that this filing is a standard proxy statement for a publicly traded biopharmaceutical company, outlining routine corporate governance matters. The focus on director elections, auditor ratification, and executive compensation is typical for annual meetings in this sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Will have the opportunity to vote on director elections, auditor ratification, and executive compensation, influencing corporate governance.
• Management: Executive compensation is subject to advisory stockholder approval, potentially influencing future compensation decisions.
• Auditors: The ratification of PwC as the independent auditor confirms their ongoing role in overseeing financial reporting.

Next Steps

• Stockholders are urged to vote their proxies promptly.
• The company will announce voting results via a Form 8-K filing within four business days after the Annual Meeting.
• Stockholder proposals for the 2027 Annual Meeting must be submitted by December 31, 2026, for inclusion in the proxy materials.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new material information regarding the company's financial performance, strategic direction, or clinical trial updates that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate based solely on this document.

Keywords

IDEAYA Biosciences, Annual Meeting, Proxy Statement, DEF 14A, Stockholder Meeting, Director Election, Auditor Ratification, Executive Compensation, Corporate Governance, SEC Filing